CAL
IOVA icon

Capital Advisors Ltd’s Iovance Biotherapeutics IOVA Stock Holding History

Capital Advisors Ltd’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-42
Closed – – 1481
2025
Q1 		$0 Sell
42
-843
-95% -$4.35K ﹤0.01% 1458
2024
Q4 		$7K Hold
885
– – ﹤0.01% 869
2024
Q3 		$8K Hold
885
– – ﹤0.01% 820
2024
Q2 		$7K Buy
+885
New +$9.48K ﹤0.01% 831
2022
Q2 		– Sell
-14
Closed – – 1153
2022
Q1 		$0 Buy
+14
New +$217 ﹤0.01% 1053

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Capital Advisors Ltd's IOVA Position: Q2 2025 in Review

Capital Advisors Ltd sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 42 shares.

Capital Advisors Ltd first reported a position in IOVA in Q1 2022 and held it in 5 quarters. The position peaked at $8K in Q3 2024. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • Capital Advisors Ltd reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Capital Advisors Ltd sold 42 Iovance Biotherapeutics shares in Q2 2025.
  • Capital Advisors Ltd first reported a position in Iovance Biotherapeutics in Q1 2022 and held it in 5 quarters.
  • Capital Advisors Ltd's Iovance Biotherapeutics position peaked at $8K in Q3 2024.
  • 254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Capital Advisors Ltd's 13F filing for Q2 2025, filed 24 Jul 2025.